$11.05
6.66% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US15687V1098
Symbol
CERT

Certara Stock price

$11.05
+0.85 8.33% 1M
-5.68 33.95% 6M
-6.54 37.18% YTD
-3.63 24.73% 1Y
-17.45 61.23% 3Y
-27.03 70.98% 5Y
-27.03 70.98% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.69 6.66%
ISIN
US15687V1098
Symbol
CERT

Key metrics

Market capitalization $1.78b
Enterprise Value $1.86b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 35.48
EV/Sales (TTM) EV/Sales 4.98
P/S ratio (TTM) P/S ratio 4.77
P/B ratio (TTM) P/B ratio 1.69
Revenue growth (TTM) Revenue growth 5.62%
Revenue (TTM) Revenue $372.80m
EBIT (operating result TTM) EBIT $1.36m
Free Cash Flow (TTM) Free Cash Flow $52.34m
Cash position $233.02m
EPS (TTM) EPS $-0.19
P/E forward negative
P/S forward 4.64
EV/Sales forward 4.85
Short interest 4.43%
Show more

Is Certara a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Certara Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Certara forecast:

4x Buy
40%
6x Hold
60%

Analyst Opinions

10 Analysts have issued a Certara forecast:

Buy
40%
Hold
60%

Financial data from Certara

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
373 373
6% 6%
100%
- Direct Costs 202 202
10% 10%
54%
171 171
0% 0%
46%
- Selling and Administrative Expenses 67 67
29% 29%
18%
- Research and Development Expense 37 37
14% 14%
10%
66 66
23% 23%
18%
- Depreciation and Amortization 65 65
19% 19%
17%
EBIT (Operating Income) EBIT 1.36 1.36
96% 96%
0%
Net Profit -31 -31
8% 8%
-8%

In millions USD.

Don't miss a Thing! We will send you all news about Certara directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Certara Stock News

Neutral
Seeking Alpha
19 days ago
Certara, Inc. (CERT) Q3 2024 Earnings Conference Call Transcript
Neutral
GlobeNewsWire
20 days ago
RADNOR, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the third quarter of fiscal year 2024.
Neutral
GlobeNewsWire
29 days ago
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the Stephens Annual Investment Conference.
More Certara News

Company Profile

Certara, Inc. engages in the provision of software and technology enables services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017 and is headquartered in Princeton, NJ.

Head office United States
CEO William Feehery
Employees 1,391
Founded 2008
Website www.certara.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today